We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Collaboration on GPCRs and Ion Channel Technology

By Biotechdaily staff writers
Posted on 03 Jun 2004
A drug discovery agreement to collaborate on G protein-coupled receptors (GPCRs) and ion channel technologies has been announced by Bionomics (Adelaide, Australia) and PerkinElmer, Inc. More...
(Boston, MA, USA).

The collaboration recognizes the value of Bionomics' ionX program for the discovery and development of ion channel drugs for central nervous system (CNS) disorders, specifically epilepsy and anxiety. Under the agreement, the two companies will collaborate on the evaluation and optimization of new ion channel reagents.

Bionomics will incorporate the Image Trak, PerkinElmer's kinetic cellular screening platform, into Bionomics' CNS drug discovery program. In addition, Bionomics will serve as a reference site for PerkinElmer's cellular screening platforms in the Asian market. Image Trak is a cellular imaging platform that utilizes patented fiberoptic imaging and fully integrated liquid handling, making it well suited for automated high-throughput screening against ion channels and GPCRs, using both standard and highly sensitive ratiometric probes.

"We look forward to further building our relationship with Bionomics and enabling them to develop the best fluorescent screening technologies available for ion channel targeted drug discovery,” said Peter Coggins, president, PerkinElmer Life and Analytical Sciences.




Related Links:
Bionomics
PerkinElmer

Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Gold Member
Quantitative POC Immunoassay Analyzer
EASY READER+
New
CMV CLIA Diagnostic
CLIA CMV IgA Screen Group
New
Immunofluorescence Analyzer
IFA System
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image

Urine-Based Multi-Cancer Screening Test Receives FDA Breakthrough Device Designation

Early detection across multiple cancers remains a major unmet need in population screening. Non-invasive approaches that can be delivered at scale may broaden access and shift diagnoses to earlier stages.... Read more

Molecular Diagnostics

view channel
Image: The new approach focuses on CpG DNA methylation, a chemical modification of cytosine and guanine bases, using tumor samples to develop a computational model that distinguishes among 21 cancer types (photo credet: 123RF)

Machine Learning Model Uses DNA Methylation to Predict Tumor Origin in Cancers of Unknown Primary

Cancers of unknown primary (CUP) are metastatic malignancies in which the primary site cannot be identified, complicating treatment selection. Many patients consequently receive broad, nonspecific chemotherapy... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.